The earnings call presented a mix of positive developments, such as leadership changes, revenue growth in some areas, and upcoming FDA decisions, alongside challenges in the oncology segment and revenue guidance adjustments.

Company Guidance

During the Jazz Pharmaceuticals 2025 Second Quarter Earnings Conference Call, the company provided several key metrics and updates. Jazz reported over $1 billion in total revenue for the second quarter, with Xywav sales increasing by 13% year-over-year, driven by approximately 625 net patient adds across narcolepsy and idiopathic hypersomnia. Epidiolex sales reached around $252 million, showing a 2% growth from the previous year, despite inventory dynamics affecting growth rates. The oncology portfolio faced near-term headwinds, with Zepzelca sales decreasing by 8% year-over-year to approximately $75 million. However, the company remains optimistic about future growth opportunities, particularly with upcoming regulatory milestones, such as the anticipated FDA approval of dordaviprone by August 18 and a PDUFA target action date of October 7 for Zepzelca in first-line maintenance for extensive stage small cell lung cancer. Jazz also revised its financial guidance, reducing the midpoint of its revenue guidance and lowering SG&A, R&D, and effective tax rate projections while raising the lower end of its ANI and EPS guidance.

Leadership Transition

Renee Gala was appointed as the new CEO, effective August 11, 2025, succeeding Bruce Cozadd. This transition is expected to build on Jazz Pharmaceuticals' momentum and drive long-term growth.

FDA PDUFA Action Dates

Jazz Pharmaceuticals is anticipating key FDA PDUFA action dates for dordaviprone on August 18, 2025, and for Zepzelca on October 7, 2025, which could potentially expand treatment options for patients.

Revenue Growth

The second quarter of 2025 saw total revenue surpass $1 billion, with Xywav showing a 13% year-over-year increase and Epidiolex maintaining strong underlying demand.

Oncology Pipeline Developments

Positive progress in the oncology pipeline includes the potential approval of dordaviprone for H3 K27M-mutant diffuse glioma and Zepzelca in first-line maintenance for extensive-stage small cell lung cancer.

Ziihera Approval

Ziihera received conditional marketing authorization from the European Commission for second-line HER2-positive biliary tract cancer, enhancing Jazz's oncology portfolio.

Jazz Pharmaceuticals (JAZZ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JAZZ Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	5.96 / -	6.61	―	―	―
Aug 05, 2025	2025 (Q2)	-7.61 / -8.25	5.3	-255.66% (-13.55)
May 06, 2025	2025 (Q1)	4.66 / 1.68	2.68	-37.31% (-1.00)
Feb 25, 2025	2024 (Q4)	5.86 / 6.60	5.02	31.47% (+1.58)
Nov 06, 2024	2024 (Q3)	5.50 / 6.61	4.84	36.57% (+1.77)
Jul 31, 2024	2024 (Q2)	4.92 / 5.30	4.51	17.52% (+0.79)
May 01, 2024	2024 (Q1)	4.18 / 2.68	3.95	-32.15% (-1.27)
Feb 28, 2024	2023 (Q4)	5.18 / 5.02	-0.07	7271.43% (+5.09)
Nov 08, 2023	2023 (Q3)	4.93 / 4.84	5.17	-6.38% (-0.33)
Aug 09, 2023	2023 (Q2)	4.45 / 4.51	4.3	4.88% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JAZZ Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$113.20	$105.93	-6.42%
May 06, 2025	$111.17	$101.44	-8.75%
Feb 25, 2025	$139.67	$144.17	+3.22%
Nov 06, 2024	$111.55	$119.08	+6.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Jazz Pharmaceuticals (JAZZ) report earnings?

Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Jazz Pharmaceuticals (JAZZ) earnings time?

Jazz Pharmaceuticals (JAZZ) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is JAZZ EPS forecast?

JAZZ EPS forecast for the fiscal quarter 2025 (Q3) is 5.96.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing